Your support fuels our research to #EndALS! Donate Now
Quick Info
Trial Type
Expanded Access
Treatment Type
Drug Trials
Start Date
Contact Information
United States, Arizona
Barrow Neurological Institute, Phoenix, AZ, 85013, United States
United States, California
University of California, San Francisco, San Francisco, CA, 94115, United States
United States, Colorado
University of Colorado, Aurora, CO, 80045, United States
United States, Connecticut
Hospital for Special Care, New Britain, CT, 06053, United States
United States, Florida
Holy Cross Hospital - Phil Smith Neuroscience Institute, Fort Lauderdale, FL, 33308, United States
Nova Southeastern University, Fort Lauderdale, FL, 33328, United States
United States, Idaho
Saint Alphonsus Regional Medical Center, Boise, ID, 83706, United States
United States, Indiana
Indiana University, Bloomington, IN, 47405, United States
United States, Iowa
University of Iowa Hospitals and Clinics, Iowa City, IA, 52242, United States
United States, Massachusetts
Sean M. Healey & AMG Center for ALS Neurological Clinical Research Institute, Massachusetts General , Boston, MA, 02114, United States
Sean M. Healey & AMG Center for ALS Neurological Clinical Research Institute, Massachusetts General , Boston, MA, 02114, United States
United States, Minnesota
University of Minnesota, Minneapolis, MN, 55455, United States
United States, Missouri
Washington University School of Medicine, Saint Louis, MO, 63110, United States
United States, New York
SUNY Upstate Medical University, Syracuse, NY, 13210, United States
United States, Pennsylvania
Thomas Jefferson University, Philadelphia, PA, 19107, United States
United States, Texas
Texas Neurology, P.A.-Neal Site:769, Dallas, TX, 75206, United States
United States, Virginia
Virginia Commonwealth University Clinical Research Unit, Richmond, VA, 23298, United States
Trial Goal
Tests to Expect
Open Label
Update Notes
Sites added
New sites added
Sites updated
Site updates, available
No significant updates
No significant updates

Other Information

This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.
Inclusion Criteria:
1. Sporadic or familial ALS.
2. Age 18 years or older.
3. Cohort 1: Patients who do not qualify for any reasonably accessible ongoing clinical trial.
4. Cohort 2: Patients who have completed the open label extension (OLE) period of Regimen E of the HEALEY ALS Platform Trial and are not eligible for enrollment in another treatment regimen of the platform study.
5. Capable of providing informed consent and complying with study procedures, in the Site Investigator's (SI's) opinion.
6. Participants have established care with a physician at the specialized ALS center involved in the study and will maintain this clinical care throughout the duration of the EAP.
7. Participants must have a life expectancy of at least 6 months in SI's opinion.
Exclusion Criteria:
1. Current diagnosis or healthcare professional-recommended treatment (medication, exercise or diet) of diabetes mellitus.
2. Screening glucose >=140 mg/dl.
3. Known hypersensitivity to trehalose.
4. Current use of oral trehalose.
5. Inability for participant to return to site for weekly drug administration, until approved for home infusions.
6. Screening body weight >144 kilograms.
7. Participant with a history of any clinically significant or unstable medical condition or lab abnormality based on the SI's judgment that may interfere with assessment of the study objectives, with safety or full participation.
8. Females who are pregnant or nursing or who plan to get pregnant during the course of the EAP.
9. Females of child-bearing potential, or males, who are unwilling or unable to use highly effective methods of birth control.
10. Use of investigational treatments for ALS (as part of participation in a clinical trial or another EAP) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Screening Visit.
11. Permanent assisted ventilation (PAV), defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days.
The date of onset of PAV is the first day of the seven days.
12. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years.
13. Presence of unstable psychiatric disease, cognitive impairment, dementia, or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion.
14. Patients who chose to take experimental medications and/or supplements, and that is the only reason they are not eligible for trials, won't be eligible for the EAP.
Approximately 70 participants receive a weekly infusion of SLS-005 for up to 24 weeks. There are 25 infusions over 24 weeks (first infusion occurs at the Screening/Baseline Visit). In addition to infusion visits, participants will have three scheduled in-clinic visits at Screening/Baseline, Week 3, and Week 24, and 2 phone call or telemedicine visits at Week 12 and approximately 28 days following the last dose of the investigational medical product.
  • Seelos Therapeutics, Inc.
Trial Protocol as Published on
NCT05597436 (First Published: 10/24/2022)